| 1. |
- Abrahamsson, Anna, et al.
(författare)
-
Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
- 2014
-
Ingår i: Blood. - : American Society of Hematology. - 1528-0020 .- 0006-4971. ; 124:8, s. 1288-1295
-
Tidskriftsartikel (refereegranskat)abstract
- There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000-2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (HR 1.36; p=0.002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3 year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3 year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n=766; HR 0.66; p=0.001) and autologous stem cell transplant (ASCT) (n=273; HR 0.55; p=0.004) were independently associated with improved overall survival in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice.
|
|
| 2. |
|
|
| 3. |
- Pedersen, Torben Brochner, et al.
(författare)
-
Use of Tromboprophylaxis in Renal Surgery in the Nordic Countries
- 2019
-
Ingår i: Scandinavian journal of urology. - : Taylor & Francis. - 2168-1805 .- 2168-1813. ; 53:Suppl. 221, s. 37-37
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Introduction: In 2017 a work panel under the European Association of Urology (EAU) pubslished the first comprehensive guideline specific to urology. The guideline offers practical evidence based guidance on use of tromboproprophylaxis (TP). Prior to this guideline publication, a previous questionaire (The NoRenCa-2 study) suggested a high degree of variation in TP practice in renal surgery across the nordic countries. We sought to examine the current practice at different urological departments accross the nordic region.Materials and Method: A questionaire was distrubuted by e-mail to urological departments performing renal surgery. The questionnaire addressed familiarity with The American College of Chest Physicians (AACP), The National Institute for Health and Care Excellence (NICE), EAU, local and national guidelines and adressed TP practice specific for renal surgical procedures.Results: Eighty-four sites were invited to complete the questionarie (reponse rate 45.9%). Participants expressed familiarity with the local (71.8%) guidelines followed by EAU (61.5%), National (41.0%) and AACP (7.7%) guidelines. Local (64.1%) guidelines was adhered to the most followed by EAU (43.6%) and National (23.1%) guidelines. For open nephrectomy, with no known risk factor for thrombosis, 94.9% offered Low Molecular Weight Heparin followed by early ambulation (69.2%), Graduated compression stockings (48.7%), Intermittent Pneumatic Compressionstockings (5.1%) and unfractionated Heparin (5.1%). A duration of 28 days (30.8%) was suggested by a majority while the remainder continued prophylaxis until discharge (20.5%), 10-14 days (5.1%), other duration (5.1%), 14-21 days (2.6%), 21-27 days (2.6%) and until ambulation(2.6%). Pharmacological TP was initiated postoperatively (56.4%) rather than preoperatively (37.2%)Conclusion: TP is used widely across the nordic countries in a majority of renal procedures. Timing, duration and type of TP nevertheless varies greatly among sites
|
|
| 4. |
- Semb, Gunvor, et al.
(författare)
-
A Scandcleft randomised trials of primary surgery for unilateral cleft lip and palate: 1. Planning and management.
- 2017
-
Ingår i: Journal of Plastic Surgery and Hand Surgery. - : Taylor & Francis. - 2000-656X .- 2000-6764. ; 51:1, s. 2-13
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND AND AIMS: Longstanding uncertainty surrounds the selection of surgical protocols for the closure of unilateral cleft lip and palate, and randomised trials have only rarely been performed. This paper is an introduction to three randomised trials of primary surgery for children born with complete unilateral cleft lip and palate (UCLP). It presents the protocol developed for the trials in CONSORT format, and describes the management structure that was developed to achieve the long-term engagement and commitment required to complete the project.METHOD: Ten established national or regional cleft centres participated. Lip and soft palate closure at 3-4 months, and hard palate closure at 12 months served as a common method in each trial. Trial 1 compared this with hard palate closure at 36 months. Trial 2 compared it with lip closure at 3-4 months and hard and soft palate closure at 12 months. Trial 3 compared it with lip and hard palate closure at 3-4 months and soft palate closure at 12 months. The primary outcomes were speech and dentofacial development, with a series of perioperative and longer-term secondary outcomes.RESULTS: Recruitment of 448 infants took place over a 9-year period, with 99.8% subsequent retention at 5 years.CONCLUSION: The series of reports that follow this introductory paper include comparisons at age 5 of surgical outcomes, speech outcomes, measures of dentofacial development and appearance, and parental satisfaction. The outcomes recorded and the numbers analysed for each outcome and time point are described in the series.TRIAL REGISTRATION: ISRCTN29932826.
|
|
| 5. |
|
|
